Medy-Tox Inc. Logo

Medy-Tox Inc.

Biopharmaceutical firm developing botulinum toxins, HA fillers, and dermocosmetics.

086900 | KO

Overview

Corporate Details

ISIN(s):
KR7086900008
LEI:
Country:
South Korea
Address:
충청북도 청원군 오창읍 각리1길 78 (주)메디톡스, 청원군

Description

Medy-Tox Inc. is a biopharmaceutical company focused on the research, development, and commercialization of biologic products. Its primary offerings are centered on botulinum toxin type A (BTX-A) formulations, including Neuronox®, INNOTOX®, Coretox®, and NEWLUX®, which are used for both aesthetic and therapeutic applications. The company is noted for developing the world's first liquid-injectable botulinum toxin. In addition to its toxin portfolio, Medy-Tox manufactures and markets a line of hyaluronic acid (HA) dermal fillers, such as Neuramis®, Atiere, and Potenfill. The company's product range also extends to dermocosmetics under the NEURADERM brand.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-11-09 00:00
투자판단관련주요경영사항(제조판매중지명령 및 품목허가취소등 취소 소송 1심 판결의 건)
Korean 9.3 KB
2023-11-08 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.5 KB
2023-11-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.4 KB
2023-11-01 00:00
주식등의대량보유상황보고서(일반)
Korean 112.2 KB
2023-10-24 00:00
투자판단관련주요경영사항(중국, 수입의약품 등록 신청 철회 결정)
Korean 7.2 KB
2023-10-23 00:00
자기주식처분결과보고서
Korean 18.0 KB
2023-10-23 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.6 KB
2023-10-17 00:00
주요사항보고서(자기주식처분결정)
Korean 65.2 KB
2023-10-11 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.4 KB
2023-10-11 00:00
현금ㆍ현물배당결정
Korean 12.1 KB
2023-09-14 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.4 KB
2023-09-11 00:00
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2023-08-11 00:00
반기보고서 (2023.06)
Korean 1.4 MB
2023-08-07 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.5 KB
2023-07-27 00:00
투자판단관련주요경영사항(제조판매중지명령 등 취소소송 및 품목허가취소 등 취소소송의 각 1심 판결에 대한 상대방(피고) 항소의 건)
Korean 9.4 KB

Automate Your Workflow. Get a real-time feed of all Medy-Tox Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medy-Tox Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medy-Tox Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.